Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Gaunt · SciRah

Researcher profile · Semantic Scholar

P. Gaunt

Share profile

P. Gaunt — researcher profile on SciRah

h-index: 14
Works: 53
Citations: 2,395

Most-cited papers

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
M. Armstrong, P. Gaunt, G. Aithal, D. Barton +12 more
2016The Lancet1,921 citations Open access
Semantic Scholar
Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.
K. Wheatley, Jayne S. Wilson, P. Gaunt, J. Marsden
2016Cancer Treatment Reviews72 citations
Semantic Scholar
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
M. Armstrong, D. Barton, P. Gaunt, D. Hull +7 more
2013BMJ Open47 citations Open access
Semantic Scholar
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.
P. Woll, P. Gaunt, Sarah J. Danson, Nicola Steele +7 more
2022Lung Cancer39 citations Open access
Semantic Scholar
Early phase clinical trials extension to guidelines for the content of statistical analysis plans
Victoria Homer, C. Yap, S. Bond, J. Holmes +15 more
2022British medical journal36 citations Open access
Semantic Scholar
Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial
A. Lorenc, M. Wells, T. Fulton-Lieuw, P. Nankivell +25 more
2021Clinics in oncology30 citations Open access
Semantic Scholar
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.
P. Nathan, P. Gaunt, K. Wheatley, S. Bowden +16 more
201626 citations
Semantic Scholar
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)
Z. Hasan, I. Ahmed, R. Matin, Victoria Homer +17 more
2022British Journal of Dermatology24 citations Open access
Semantic Scholar
P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC: Topic: Drug Treatment Alone and in Combination with Radiotherapy
P. Woll, P. Gaunt, Nicola Steele, Samreen I. Ahmed +8 more
201720 citations Open access
Semantic Scholar
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma
L. Forker, P. Gaunt, S. Sioletic, P. Shenjere +12 more
2017British Journal of Cancer20 citations Open access
Semantic Scholar
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
D. Ferry, L. Billingham, H. Jarrett, D. Dunlop +15 more
2017European Journal of Cancer19 citations Open access
Semantic Scholar
Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer.
S. Meade, P. Gaunt, A. Hartley, Max Robinson +7 more
2018Clinics in oncology17 citations
Semantic Scholar
Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE).
H. Mehanna, M. Sen, J. Chester, P. Sanghera +16 more
201715 citations
Semantic Scholar
Vortex Trial: A Randomized Controlled Multicenter Phase 3 Trial of Volume of Postoperative Radiation Therapy Given to Adult Patients With Extremity Soft Tissue Sarcoma (STS).
M. Robinson, P. Gaunt, R. Grimer, B. Seddon +11 more
201614 citations Open access
Semantic Scholar
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
H. Mehanna, P. Gaunt, Anthony Kong, A. Hartley +19 more
2024Trials13 citations Open access
Semantic Scholar
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
P. Woll, P. Gaunt, C. Gaskell, Robin Young +11 more
2023British Journal of Cancer13 citations Open access
Semantic Scholar
Systematic review of patients’ and healthcare professionals’ views on patient‐initiated follow‐up in treated cancer patients
J. Dretzke, A. Lorenc, Ada Adriano, Clare P. Herd +24 more
2023Cancer Medicine13 citations Open access
Semantic Scholar
G01 : Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebo-controlled phase II trial
M. Armstrong, P. Gaunt, G. Aithal, R. Parker +10 more
201512 citations
Semantic Scholar
PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial
P. Nankivell, P. Gaunt, C. Gaunt, J. Sissons +5 more
2024BMC Cancer8 citations Open access
Semantic Scholar
S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients
L. Billingham, P. Gaunt, H. Jarrett, David Dunlop +14 more
2011Thorax7 citations Open access
Semantic Scholar
Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy
M. J. Armstrong, P. Gaunt, P. Newsome
2016Hepatology6 citations Open access
Semantic Scholar
Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma
L. Forker, B. Bibby, Ling-Jian Yang, B. Lane +14 more
2023British Journal of Cancer5 citations Open access
Semantic Scholar
1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)
H. M. Mehanna, P. Gaunt, M. Forster, A. Kong +16 more
2025Annals of Oncology4 citations Open access
Semantic Scholar
OC-016 Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase ii trial
M. J. Armstrong, P. Gaunt, G. Aithal, R. Parker +10 more
20154 citations
Semantic Scholar
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.
Brennan Bernadette, L. Kirton, P. Marec-Bérard, Nathalie Gaspar +12 more
2026British Journal of Cancer2 citations Open access
Semantic Scholar
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose–volume constraints development: a study protocol
R. Simões, Sarah Gulliford, Beatrice M. Seddon, H. Dehbi +12 more
2024BMJ Open2 citations Open access
Semantic Scholar
Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial
Amit Patel, Kristian Brock, Daniel Slade, C. Gaunt +4 more
2024BMC Medical Research Methodology2 citations Open access
Semantic Scholar
The design of a multi-arm multi-stage (MAMS) phase III randomised controlled trial comparing alternative regimens for escalating (COMPARE) treatment of intermediate and high-risk oropharyngeal cancer with reflections on the complications of introducing a new experimental ARM
P. Gaunt, H. Mehanna, C. Yap
2015Trials2 citations Open access
Semantic Scholar
Developing a standardized actinic keratosis assessment protocol
R. Matin, P. Gaunt, D. McCartney, F. Ismail +5 more
20132 citations Open access
Semantic Scholar
Promoting engagement in patient-initiated follow-up and self-care behaviours: acceptability of the ‘ACT now & check-it-out’ intervention for head and neck cancer (PETNECK2 study)
Lauren Matheson, Eila Watson, T. Fulton-Lieuw, Saloni Mittal +7 more
2026BMJ Open1 citations Open access
Semantic Scholar
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer
D. Ferry, L. Billingham, H. Jarrett, P. Woll +13 more
20171 citations
Semantic Scholar
Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial
M. Armstrong, D. Hull, K. Guo, D. Barton +8 more
20131 citations
Semantic Scholar
Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial.
Yuan Liu, M. Fiocco, Laura Kirton, P. Gaunt +3 more
2026European Journal of Cancer0 citations Open access
Semantic Scholar
1386 Impact of the introduction of “5+5” contouring on efficacy and swallowing outcomes in the phase 3 randomised CompARE trial.
Charles Fong, P. Gaunt, Paul Sanghera, A. Cristaudo +5 more
2025Radiotherapy and Oncology0 citations
Semantic Scholar
3942 Preliminary dose-volume constraints predicting subcutaneous tissue fibrosis for limb sarcoma using the VorteX and IMRiS trials.
Rita Simões, Beatrice M. Seddon, Martin Robinson, S. Shelly +9 more
2025Radiotherapy and Oncology0 citations
Semantic Scholar
Phase II assessment of carboplatin with etoposide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
Martin G. McCabe, L. Kirton, Maria Khan, Sandra J. Strauss +16 more
2025Journal of Clinical Oncology0 citations
Semantic Scholar
PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS
Rita Simões, Beatrice M. Seddon, Martin Robinson, S. Shelly +9 more
2025ESMO Rare Cancers0 citations Open access
Semantic Scholar
Development and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012
Laura Kirton, R. Riley, P. Gaunt, B. Brennan +1 more
2024BMJ Open0 citations Open access
Semantic Scholar
Correction: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial
P. Nankivell, P. Gaunt, C. Gaunt, J. Sissons +28 more
2024BMC Cancer0 citations Open access
Semantic Scholar
PO-2279 Preliminary analysis of subcutaneous tissue fibrosis and dose-volume relationships for limb sarcoma
R. Simões, S. Gulliford, B. Seddon, M. Robinson +9 more
2023Radiotherapy and Oncology0 citations
Semantic Scholar
MO-0947 Lessons learned from RT toxicity outcomes from UK VorteX and IMRiS trials for limb sarcoma
R. Simões, H. Dehbi, S. Gulliford, B. Seddon +9 more
2023Radiotherapy and Oncology0 citations
Semantic Scholar
Partnership.
Victoria Homer, Christina Yap, Simon Bond, J. Holmes +15 more
2022The Veterinary Record0 citations
Semantic Scholar
OC-0086: A sarcoma hypoxia signature (nanoString® assay) validates in the phase III VorteX radiotherapy trial
L. Forker, B. Bibby, Ling-Jian Yang, Joely J. Irlam +9 more
20200 citations
Semantic Scholar
Nephrology In-Reach Services Lead to Improvement in Mortality in Acute Kidney Injury – 3 (AKI-3)
E. Gkekas, TYT. Tang, M. Brazell, M. Brennan +9 more
20200 citations Open access
Semantic Scholar
cell lung cancer : Results from a British Thoracic Oncology Group randomised phase III trial
D. Ferry, L. Billingham, H. Jarrett, P. Woll +13 more
20170 citations
Semantic Scholar
Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76.
K. Wheatley, Jayne S. Wilson, P. Gaunt, J. Marsden
2017Cancer Treatment Reviews0 citations Open access
Semantic Scholar
Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
P. Newsome, M. Armstrong, P. Gaunt
2016The Lancet0 citations Open access
Semantic Scholar
Evaluation of biomarkers in the UK phase III VorteX trial confirms importance of tumour hypoxia in soft tissue sarcoma
L. Forker, P. Gaunt, S. Sioletic, P. Shenjere +7 more
20160 citations
Semantic Scholar
The hypoxia marker CA-IX is prognostic in soft tissue sarcoma patients treated in the UK phase III VORTEX trial
L. Forker, S. Sioletic, P. Shenjere, Joely J. Irlam +6 more
20160 citations
Semantic Scholar
PO-088: Chemoradiotherapy for poor/intermediate risk oropharyngeal carcinoma: First results of the ArCHIMEDEs study
V. Harrop, S. Meade, L. Wagstaff, J. Babrah +6 more
20150 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Billingham×12
Invite
L. Billingham — researcher profile on SciRah
P. Woll×7
Invite
P. Woll — researcher profile on SciRah
C. Gaunt×7
Invite
C. Gaunt — researcher profile on SciRah
R. Shah×6
Invite
R. Shah — researcher profile on SciRah

×6

Invite

P. Nankivell — researcher profile on SciRah

Invite

A. Hughes — researcher profile on SciRah

M. Armstrong×5

Invite

M. Armstrong — researcher profile on SciRah

Invite

D. Barton — researcher profile on SciRah

Invite

K. Guo — researcher profile on SciRah

Invite

P. Newsome — researcher profile on SciRah

T. Fulton-Lieuw×5

Invite

T. Fulton-Lieuw — researcher profile on SciRah

Invite

H. Mehanna — researcher profile on SciRah